171 related articles for article (PubMed ID: 24590773)
41. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
[TBL] [Abstract][Full Text] [Related]
42. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
43. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
Wang J; Lu K; Song Y; Zhao S; Ma W; Xuan Q; Tang D; Zhao H; Liu L; Zhang Q
PLoS One; 2015; 10(7):e0133964. PubMed ID: 26218592
[TBL] [Abstract][Full Text] [Related]
44. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
[TBL] [Abstract][Full Text] [Related]
45. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
47. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
48. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Mao JJ; Su HI; Feng R; Donelson ML; Aplenc R; Rebbeck TR; Stanczyk F; DeMichele A
Breast Cancer Res; 2011 Jan; 13(1):R8. PubMed ID: 21251330
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
50. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
51. Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Reinbolt RE; Sonis S; Timmers CD; Fernández-Martínez JL; Cernea A; de Andrés-Galiana EJ; Hashemi S; Miller K; Pilarski R; Lustberg MB
Cancer Med; 2018 Jan; 7(1):240-253. PubMed ID: 29168353
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H; Aristarco V; Gandini S; Gjerde J; Macis D; Guerrieri-Gonzaga A; Serrano D; Lazzeroni M; Rajasekaran A; Williard CV; Mellgren G; DeCensi A; Bonanni B
Pharmacogenomics J; 2020 Feb; 20(1):19-26. PubMed ID: 30967597
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Sini V; Botticelli A; Lunardi G; Gori S; Marchetti P
Pharmacogenomics; 2017 Jun; 18(8):821-830. PubMed ID: 28592202
[TBL] [Abstract][Full Text] [Related]
54. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
Rodríguez-Sanz M; García-Giralt N; Prieto-Alhambra D; Servitja S; Balcells S; Pecorelli R; Díez-Pérez A; Grinberg D; Tusquets I; Nogués X
J Mol Endocrinol; 2015 Aug; 55(1):69-79. PubMed ID: 26108486
[TBL] [Abstract][Full Text] [Related]
55. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
[TBL] [Abstract][Full Text] [Related]
56. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Wang L; Ellsworth KA; Moon I; Pelleymounter LL; Eckloff BW; Martin YN; Fridley BL; Jenkins GD; Batzler A; Suman VJ; Ravi S; Dixon JM; Miller WR; Wieben ED; Buzdar A; Weinshilboum RM; Ingle JN
Cancer Res; 2010 Jan; 70(1):319-28. PubMed ID: 20048079
[TBL] [Abstract][Full Text] [Related]
57. Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population.
Al-Eitan LN; Rababa'h DM; Alghamdi MA; Khasawneh RH
BMC Med Genet; 2019 Sep; 20(1):148. PubMed ID: 31477036
[TBL] [Abstract][Full Text] [Related]
58. Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension.
Coban N; Onat A; Guclu-Geyik F; Can G; Erginel-Unaltuna N
Arch Med Res; 2015 Oct; 46(7):564-71. PubMed ID: 26415088
[TBL] [Abstract][Full Text] [Related]
59. Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Fukami M; Suzuki J; Nakabayashi K; Tsunashima R; Ogata T; Shozu M; Noguchi S
Breast Cancer; 2014 May; 21(3):382-5. PubMed ID: 23625277
[TBL] [Abstract][Full Text] [Related]
60. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Liu M; Ingle JN; Fridley BL; Buzdar AU; Robson ME; Kubo M; Wang L; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Goetz MP; Northfelt DW; Perez EA; Williard CV; Schaid DJ; Nakamura Y; Weinshilboum RM
Mol Endocrinol; 2013 Apr; 27(4):657-70. PubMed ID: 23518928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
